Physician profile
Jonathan Datar
NPI 1316333016
$25,095.42
in general payments reported to CMS, 2019-2025
54 companies · $3,995 in 2025
The $3,995 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $640 · 2021: $4,183 · 2022: $4,473 · 2023: $5,038 · 2024: $6,393 · 2025: $3,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,169.32 |
| Education | $256.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,818.22 | 2020-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $2,773.52 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $2,734.67 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Novartis Pharmaceuticals Corporation | $2,025.29 | 2021-2025 | |
| Tg Therapeutics, INC. | $1,360.19 | 2023-2025 | |
| Genzyme Corporation | $1,042.70 | 2019-2025 | |
| Lilly USA, LLC | $1,026.26 | 2021-2025 | Emgality, Reyvow, Amyvid |
| Ucb, INC. | $902.45 | 2022-2025 | Nayzilam, Briviact, Rystiggo |
| Biohaven Pharmaceuticals, INC. | $759.41 | 2020-2021 | |
| Celgene Corporation | $664.64 | 2021-2024 | Zeposia |
| Argenx US, INC. | $634.36 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $611.16 | 2019-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $596.31 | 2020-2025 | Uplizna, Tepezza, Aimovig |
| Teva Pharmaceuticals USA, INC. | $554.64 | 2021-2024 | Austedo Xr, Ajovy |
| Lundbeck LLC | $549.68 | 2021-2025 | Vyepti |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Datar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.